Table 1.
Clinicopathological characteristics of five immunotherapy cohorts included in this study.
| Patient characteristics | Training cohorts | Validation cohorts | |||
|---|---|---|---|---|---|
| Gide19 | Hugo16 | Riaz17 | VanAllen15 | PUCH | |
| No. of patients | 41 | 28 | 51 | 42 | 55 |
| Median age in yrs (range) | 66 (37-90) | 61 (19-84) | – | 61 (22-83) | 51 (27-72) |
| Sex, n (%) | |||||
| Male | 26 (63.4) | 20 (71.4) | – | 28 (66.7) | 17 (30.9) |
| Female | 15 (36.6) | 8 (28.6) | – | 14 (33.3) | 38 (69.1) |
| Primary site, n (%) | |||||
| Acral | – | – | 1 (2.0) | – | 24 (43.6) |
| Mucosal | – | 3 (10.7) | 7 (13.7) | 2 (4.8) | 8 (14.5) |
| Cutaneous | – | 21 (75.0) | 32 (62.7) | 37 (88.1) | 18 (32.7) |
| Ocular | – | 4 (7.9) | 3 (7.1) | – | |
| Unknown | – | 4 (14.3) | 7 (13.7) | – | 5 (9.1) |
| Metastasis status, n (%) | |||||
| M0 | – | 1 (3.6) | 1 (1.9) | 1 (2.4) | 10 (18.2) |
| M1a | – | 2 (7.1) | 11 (21.6) | 3 (7.1) | 16 (29.1) |
| M1b | – | 3 (10.7) | 8 (15.7) | 7 (16.7) | 18 (32.7) |
| M1c | – | 22 (78.6) | 23 (45.1) | 31 (73.8) | 11 (20.0) |
| Unknown | – | – | 8 (15.7) | – | – |
| BRAF V600, n (%) | – | 12 (42.9) | 14 (27.4) | – | – |
| Prior MAPKi, n (%) | – | 12 (42.9) | – | 4 (9.5) | – |
| Treatment, n (%) | |||||
| Anti-PD-1 | 41 (100) | 28 (100) | 51 (100) | – | 55 (100) |
| Anti-CTLA-4 | – | – | – | 42 (100) | |
| Best overall response, n (%) | |||||
| CR | 4 (9.8) | 5 (17.9) | 3 (5.9) | – | 1 (1.8) |
| PR | 15 (36.6) | 10 (35.7) | 7 (13.7) | – | 13 (23.6) |
| CR/PR | – | – | 19 (45.2) | ||
| SD | 6 (14.6) | – | 16 (31.4) | – | 6 (10.9) |
| PD | 16 (39.0) | 13 (46.4) | 25 (49.0) | 23 (54.8) | 35 (63.6) |
| Median PFS (months) | 9.0 | – | – | 2.8 | 3.9 |
| Median OS (months) | 29.3 | 32.7 | 21.1 | 13.1 | 28.1 |
MAPKi, MAPK pathway inhibitors; Anti-PD-1, anti-programmed death-1; Anti-CTLA-4, anti-cytotoxic T lymphocyte antigen-4; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival.